메뉴 건너뛰기




Volumn 120, Issue 12, 2014, Pages 1830-1837

The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States

Author keywords

follicular lymphoma; frontline therapy; non Hodgkin lymphoma; outcomes; rituximab maintenance

Indexed keywords

RITUXIMAB;

EID: 84902194519     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28659     Document Type: Article
Times cited : (30)

References (19)
  • 1
    • 1842413105 scopus 로고    scopus 로고
    • A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project
    • A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997; 89: 3909-3918.
    • (1997) Blood , vol.89 , pp. 3909-3918
  • 2
    • 54849426881 scopus 로고    scopus 로고
    • Classification updates and clinical investigations in indolent non-Hodgkin lymphoma
    • Cheson BD,. Classification updates and clinical investigations in indolent non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2008; 6: 4-6.
    • (2008) Clin Adv Hematol Oncol , vol.6 , pp. 4-6
    • Cheson, B.D.1
  • 3
    • 0027376013 scopus 로고
    • Natural history of and therapy for the indolent non-Hodgkin's lymphomas
    • (5 suppl).
    • Horning SJ,. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol. 1993; 20 (5 suppl 5): 75-88.
    • (1993) Semin Oncol , vol.20 , Issue.5 , pp. 75-88
    • Horning, S.J.1
  • 4
    • 62449324950 scopus 로고    scopus 로고
    • Follicular lymphoma in the United States: First report of the national LymphoCare study
    • Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol. 2009; 27: 1202-1208.
    • (2009) J Clin Oncol , vol.27 , pp. 1202-1208
    • Friedberg, J.W.1    Taylor, M.D.2    Cerhan, J.R.3
  • 5
    • 84865835283 scopus 로고    scopus 로고
    • A comparison of the effectiveness of first-line chemoimmunotherapy regimens for follicular lymphoma (fl) used in the United States [abstract]
    • Abstract 97
    • Nastoupil L, Sinha R, Byrtek M, et al. A comparison of the effectiveness of first-line chemoimmunotherapy regimens for follicular lymphoma (fl) used in the United States [abstract]. Blood. 2011; 118:Page 47. Abstract 97.
    • (2011) Blood , vol.118 , pp. 47
    • Nastoupil, L.1    Sinha, R.2    Byrtek, M.3
  • 6
    • 0028835315 scopus 로고
    • Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center
    • Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol. 1995; 13: 140-147.
    • (1995) J Clin Oncol , vol.13 , pp. 140-147
    • Johnson, P.W.1    Rohatiner, A.Z.2    Whelan, J.S.3
  • 7
    • 0037108822 scopus 로고    scopus 로고
    • Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma
    • 3rd, et al.
    • Hainsworth JD, Litchy S, Burris HA, 3rd, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol. 2002; 20: 4261-4267.
    • (2002) J Clin Oncol , vol.20 , pp. 4261-4267
    • Hainsworth, J.D.1    Litchy, S.2    Burris, H.A.3
  • 8
    • 33749545033 scopus 로고    scopus 로고
    • Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial
    • van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006; 108: 3295-3301.
    • (2006) Blood , vol.108 , pp. 3295-3301
    • Van Oers, M.H.1    Klasa, R.2    Marcus, R.E.3
  • 9
    • 33845515497 scopus 로고    scopus 로고
    • German Low Grade Lymphoma Study Group (GLSG). Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas
    • Forstpointner R, Unterhalt M, Dreyling M, et al. German Low Grade Lymphoma Study Group (GLSG). Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006; 108: 4003-4008.
    • (2006) Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG) , vol.108 , pp. 4003-4008
    • Forstpointner, R.1    Unterhalt, M.2    Dreyling, M.3
  • 10
    • 2942567554 scopus 로고    scopus 로고
    • Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly ×4 schedule
    • Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly ×4 schedule. Blood. 2004; 103: 4416-4423.
    • (2004) Blood , vol.103 , pp. 4416-4423
    • Ghielmini, M.1    Schmitz, S.F.2    Cogliatti, S.B.3
  • 11
    • 78650823247 scopus 로고    scopus 로고
    • Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial
    • Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011; 377: 42-51.
    • (2011) Lancet , vol.377 , pp. 42-51
    • Salles, G.1    Seymour, J.F.2    Offner, F.3
  • 12
    • 77956413908 scopus 로고    scopus 로고
    • Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Long-term outcome of the EORTC 20981 phase III randomized intergroup study
    • van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010; 28: 2853-2858.
    • (2010) J Clin Oncol , vol.28 , pp. 2853-2858
    • Van Oers, M.H.1    Van Glabbeke, M.2    Giurgea, L.3
  • 13
    • 63749097149 scopus 로고    scopus 로고
    • Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: Results of the randomized phase III ECOG1496 Study
    • Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol. 2009; 27: 1607-1614.
    • (2009) J Clin Oncol , vol.27 , pp. 1607-1614
    • Hochster, H.1    Weller, E.2    Gascoyne, R.D.3
  • 14
    • 14544276412 scopus 로고    scopus 로고
    • Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma-A randomized phase II trial of the Minnie Pearl Cancer Research Network
    • Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA,. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma-a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005; 23: 1088-1095.
    • (2005) J Clin Oncol , vol.23 , pp. 1088-1095
    • Hainsworth, J.D.1    Litchy, S.2    Shaffer, D.W.3    Lackey, V.L.4    Grimaldi, M.5    Greco, F.A.6
  • 15
    • 84867400613 scopus 로고    scopus 로고
    • Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A randomized phase III study comparing 2 different rituximab dosing strategies for low tumor burden follicular lymphoma [abstract]
    • Abstract LBA-6
    • Kahl B, Fangxin H, Williams ME, et al. Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): a randomized phase III study comparing 2 different rituximab dosing strategies for low tumor burden follicular lymphoma [abstract]. Blood. 2011; 118:Page. Abstract LBA-6.
    • (2011) Blood , vol.118
    • Kahl, B.1    Fangxin, H.2    Williams, M.E.3
  • 16
    • 84877359983 scopus 로고    scopus 로고
    • Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections
    • Casulo C, Maragulia J, Zelenetz AD,. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk. 2013; 13: 106-111.
    • (2013) Clin Lymphoma Myeloma Leuk , vol.13 , pp. 106-111
    • Casulo, C.1    Maragulia, J.2    Zelenetz, A.D.3
  • 17
    • 70350776531 scopus 로고    scopus 로고
    • Good research practices for comparative effectiveness research: Defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report-Part i
    • Berger ML, Mamdani M, Atkins D, Johnson ML,. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report-Part I. Value Health. 2009; 12: 1044-1052.
    • (2009) Value Health , vol.12 , pp. 1044-1052
    • Berger, M.L.1    Mamdani, M.2    Atkins, D.3    Johnson, M.L.4
  • 18
    • 70350780206 scopus 로고    scopus 로고
    • Good research practices for comparative effectiveness research: Approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: The International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report-Part II
    • Cox E, Martin BC, Van Staa T, Garbe E, Siebert U, Johnson ML,. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report-Part II. Value Health. 2009; 12: 1053-1061.
    • (2009) Value Health , vol.12 , pp. 1053-1061
    • Cox, E.1    Martin, B.C.2    Van Staa, T.3    Garbe, E.4    Siebert, U.5    Johnson, M.L.6
  • 19
    • 70350776529 scopus 로고    scopus 로고
    • Good research practices for comparative effectiveness research: Analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report-Part III
    • Johnson ML, Crown W, Martin BC, Dormuth CR, Siebert U,. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report-Part III. Value Health. 2009; 12: 1062-1073.
    • (2009) Value Health , vol.12 , pp. 1062-1073
    • Johnson, M.L.1    Crown, W.2    Martin, B.C.3    Dormuth, C.R.4    Siebert, U.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.